Member Info for potnak

Weird comment, Laz. Why does Ahfams day have to come? Does he deserve some sort of prize for not getting it right over and over? What about Puma? Has his day come? I mean, he did get if right, so we should thank him, yes? The RNS today is good news, another milestone reached but it also reiterates the timelines we are on and there are no shortcuts on safety. When the data is in the the deal is, done. It won't have anything to do with what Puma, Ahfam or anyone said on here. It will be the science and the boards deal making skills. So with that said isn't that where we should be looking when things aren't going the way they told us it would? The RF facility is a bad deal for investors. Saying it was the only option isn't the flex some here think it is. This was our boards only option and I'm willing to give them the benefit of doubt but they are the ones in control here. Win or lose, it's on them. Not Ahfam or Puma or MHRA or Covid etc. etc. I don't think a bit scrutiny and focus on the board is a bad thing right now.

I don't think I do anything more that sit on the fence but as long as you are happy for a potential 40 or even 30p. Your won't be too disappointed. The RF facility is structured in a way that that they can't lose, no matter how low the sp goes. If you think that is negative then🤷🏻‍♂️

Aber - this, exactly. I'm not sure why people are mad at Puma for basically getting the call right. And even if he has made money shorting it, good. At least someone is. Our late great Thoth used to do the same as puma on other boards. Listening to thoth, saved me cash on 2 occasions. Some posters here get too entrenched in their view of SAR. So much so that it clouds their judgement and they end up sidingg with those that have the same view. Worse though. They attack the ones that are calling it right.

I'll say it again, the only posters that have got predictions right since summer 2021 are the so called wombles. The rerate boy have been wrong over and over.

I'm holding here because there is no point selling now but strangely, I think the risk of failure for financial reasons is higher than it has ever been. I'll say this again too. Not all failed AIM companies had a failed product. Some were just mismanaged into obscurity. I predict a long painful winter. Hopefully with something really positive to report in spring.

I've been in a p2 share that gif not meet primary endpoint. 90% value gone in 1 day, not good. I also watched the IMM saga unfold after the late Thoth says they had messed up the trial design up. He got called all the names others get called here. I listened but others didn't and lost big time. Truth is that although their intentions might be scetchy, there is usually dome truth or reality to the cashers claims. As the RF facility has shown here. My advice is to have your own plan and stick to it.

Risk versus reward benHowell. You could always sell when anticipation of p2 data is due.

I understand why some may think Parkers tweet is cynical but rules around what you can and can't say in public are strict. He said they were having Sareum PLC meeting whilst in Munich. I believe him. However, the meeting could be about who cleans the office in Pampisford and it still would be true. Personally, I'm choosing to think the meetings are something that will progress the company.

Companies in the Munich region

Well-known national and international companies are based in Munich and the surrounding region.

They include

Amgen GmbH

Aenova

Astellas Pharma

Bavarian Nordic GmbH

bene-Arzneimittel GmbH

Biogen GmbH

Bristol-Myers Squibb (BMS)

GlaxoSmithKline (GSK)

Hexal

Moderna

MorphoSys

Neovii Biotech GmbH

Roche Diagnostics

Maybe Parkers comment to the tweet is a nod to conversations with prospective partners? Any major pharma based in Munich.

Just checked. It was 1 share for every 3 subscription shares held. When you compare this fundraising to the RF facility, it's light years apart and I can't think the HNWI investors are too happy how this worked out.

I don't think there were any restrictions on selling the shares. The 5 year period was based on buying more as warrants. That deal will still stand, if the HNWI still holds shares. Theyd be quids in if a deal landed that made the shares worth £20. The HNWI would be able to buy a load, can't remember the figure, something like 1 share for every share they owned but they'd be able to buy them for 7p or 350p in today's money.

I've said before that I don't think Australia was chosen for the trials, just because we speak the same language. I think there is more to it. Australia also does lots of trade with the asian markets. The Chinese and now Japanese patents are a big deal IMO. If we were targeting the European or US matkets, I think we would have picked a lab in those locations.

Yes, you missed something. Shares were consolidated at 50:1 so 30p was 0.6p not far off my and most LTH averages.

As, usuall, context is key and both opions are could come true. Look at the link HBD posted below. If sareum got a similar licence for 1801, say £120 million upfront and £1.2 billion in milestones and say we got the same figures for 1802. That's £240 million in the bank with nothing to spend it on, although Tim did say they may aquire a compound in the future. And on top of that we would have a potential 2.4 billion in milestones to come. We'd be over £5 again, possibly nearer £10. Then as we inch towards market the sp would rise with every milestone reached. By the the end of 1801 p2 and good data from 1802 phase 1b. We could easily but on a valuation of £2 billion, and if course, you would be free to sell and buy anywhere you want in that cycle. On the filp side, if anything goes wrong with 1801, we lose almost everything. A buyout would be nice but would also come with a penalty and we'd see a big discount. The MA guys can answer this one but it wouldn't be unusual to see a 50 to 75% discount on the potential if an offer was made. In this scenario, the board would recommend whether it a good deal or not. A lot of flak is thrown at the NEDS but IMO they have very little to do with the day to day running of the company, they are here for regulatory reasons and one those reasons is TO, especially hostile takeovers, they will be on a fractional salary as a retainer so when/if the time comes they can recommend which way the shareholders vote. Tim and John aren't in a position to do this.

It doesn't really matter what you, I or any of the shareholders want to happen. The deal will be negotiated without our knowledge. If its a licence and they were pretty clear that was what they are aiming for then we will get an RNS and that will be that. All I'm saying is there is a window of opportunity for a TO before a licence is inked. The board would have to put that offer to a shareholder vote with recommendations of which way to vote.

Personally, I think there is shrinking window of opportunity for a full TO and that might actually work in the shareholders favour in terms of timescales and market sentiment. IMO, once a licence deal is done then that's it, we wait for trials and milestones to filter through and the market cap will be directly linked to progress and cash in the bank.

Whether 737 is good or not. We are lucky we have it in our back pocket, otherwise IMO, we'd be back under a penny in old money. I don't think we will initialise p1 trials for 1802, if it is going to be licenced, it will be preclinical based on what happens with 1801. We will do the translational studies just to make it a neat package then hand over the data. If 1801 p1b goes well, 1802 will sell itself.

I still think that 737 will be the key to what happens to Sareum in the future. I don't think there is any doubt of the potential of 737 and sareums 27.5% is an obvious insurance for any deals made for 1801/2 but that in itself could cause complex contractual issues for any licensee of the tyk2 compounds. As SOG says, this will take some working out unless all licences goto the same pharma. Question is, who has the compounds that could benefit from adding 737 into the mix and do they also have a hole in the pipeline that tyk2 could fill. I'm not expecting anything soon but I think the news from both will come together.

Aye, Ben. I've no issue with shorters. If you are in the market, you are fair game IMO. I've always said it. There is no moral highground to take when investing. We all want to sell at the high point and TO aside, if you manage to sell at an all time high. Someone bought those shares and will lose money. Nothing that Puma or Maj has said is incorrect in fact they nailed it and if any of us had have listened, then we could have sold and bought back double the amount of shares. The only thing stopping me personally is 737, because as you say that could happen anytime. Too much risk and FOMO for me to sell. Just tint engage with them. You don't need to justify why you hold. Thoth used to be mischievous sometimes and would follow the likes of Puma and Maj to other share boards to discredit them in front of their mates as it were. No condoning that sort of thing but it was funny to see.

Have to agree with DeAar here. The RNS and IM presentation were clear. P1a data readout by H1 2024. Not sure why you would torture yourself thinking it will be this year. The only timeline we don't know is 737, that could come anytime.

I think, although we only have a 27.5% interest in 737 that 737 is or has been been the catalyst for all that has happened in the last 2 or 3 years. It was anticipated that under Sierra, the milestones would pay for tyk2 trials, it didn't so we got some HNWI investment. Then we thought GSK would do something with, they didn't so we looked for other ways to finance tyk2 and we got riverfort. Now with the riverfort facility in place. I do think the future if 737 will decide whether we sell the whole company or whether we on licence the tyk2 compounds. The board are obviously aiming for an on licence because, that's all they can do but if 737 suddenly gives us a potential share of a big market, then an outright buyout starts to make more sense. What we should probably ask is who has a PD1 and a hole in their pipeline for tyk2 compound.